255 related articles for article (PubMed ID: 8980410)
1. Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity.
Bokemeyer C; Fels LM; Dunn T; Voigt W; Gaedeke J; Schmoll HJ; Stolte H; Lentzen H
Br J Cancer; 1996 Dec; 74(12):2036-41. PubMed ID: 8980410
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin nephrotoxicity and protection by silibinin.
Gaedeke J; Fels LM; Bokemeyer C; Mengs U; Stolte H; Lentzen H
Nephrol Dial Transplant; 1996 Jan; 11(1):55-62. PubMed ID: 8649653
[TBL] [Abstract][Full Text] [Related]
3. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
[TBL] [Abstract][Full Text] [Related]
4. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A
Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038
[TBL] [Abstract][Full Text] [Related]
5. Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats.
Humanes B; Lazaro A; Camano S; Moreno-Gordaliza E; Lazaro JA; Blanco-Codesido M; Lara JM; Ortiz A; Gomez-Gomez MM; Martín-Vasallo P; Tejedor A
Kidney Int; 2012 Sep; 82(6):652-63. PubMed ID: 22718191
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer.
Motzer RJ; Sheinfeld J; Mazumdar M; Bains M; Mariani T; Bacik J; Bajorin D; Bosl GJ
J Clin Oncol; 2000 Jun; 18(12):2413-8. PubMed ID: 10856101
[TBL] [Abstract][Full Text] [Related]
8. The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors.
Hartmann JT; Knop S; Fels LM; van Vangerow A; Stolte H; Kanz L; Bokemeyer C
Anticancer Drugs; 2000 Jan; 11(1):1-6. PubMed ID: 10757556
[TBL] [Abstract][Full Text] [Related]
9. Protection against cisplatin-induced nephrotoxicity by Spirulina in rats.
Mohan IK; Khan M; Shobha JC; Naidu MU; Prayag A; Kuppusamy P; Kutala VK
Cancer Chemother Pharmacol; 2006 Dec; 58(6):802-8. PubMed ID: 16552571
[TBL] [Abstract][Full Text] [Related]
10. Vascular neurotoxicity following chemotherapy with cisplatin, ifosfamide, and etoposide.
Dietrich J; Marienhagen J; Schalke B; Bogdahn U; Schlachetzki F
Ann Pharmacother; 2004 Feb; 38(2):242-6. PubMed ID: 14742759
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin nephrotoxicity is mediated by gamma glutamyltranspeptidase, not via a C-S lyase governed biotransformation pathway.
Wainford RD; Weaver RJ; Stewart KN; Brown P; Hawksworth GM
Toxicology; 2008 Jul; 249(2-3):184-93. PubMed ID: 18583013
[TBL] [Abstract][Full Text] [Related]
12. The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna.
Bokemeyer C; Schmoll HJ; Ludwig E; Harstrick A; Dunn T; Casper J
Br J Cancer; 1994 May; 69(5):863-7. PubMed ID: 8180015
[TBL] [Abstract][Full Text] [Related]
13. Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma.
Koch Nogueira PC; Hadj-Aïssa A; Schell M; Dubourg L; Brunat-Mentigny M; Cochat P
Pediatr Nephrol; 1998 Sep; 12(7):572-5. PubMed ID: 9761357
[TBL] [Abstract][Full Text] [Related]
14. Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome.
Beyer J; Rick O; Weinknecht S; Kingreen D; Lenz K; Siegert W
Bone Marrow Transplant; 1997 Nov; 20(10):813-9. PubMed ID: 9404920
[TBL] [Abstract][Full Text] [Related]
15. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
[TBL] [Abstract][Full Text] [Related]
16. Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines.
Klaassen U; Harstrick A; Schleucher N; Vanhoefer U; Schröder J; Wilke H; Seeber S
Br J Cancer; 1996 Jul; 74(2):224-8. PubMed ID: 8688325
[TBL] [Abstract][Full Text] [Related]
17. Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma.
Arndt C; Morgenstern B; Hawkins D; Wilson D; Liedtke R; Miser J
Med Pediatr Oncol; 1999 Feb; 32(2):93-6. PubMed ID: 9950195
[TBL] [Abstract][Full Text] [Related]
18. Children's toxicology from bench to bed--Drug-induced renal injury (2): Nephrotoxicity induced by cisplatin and ifosfamide in children.
Fujieda M; Matsunaga A; Hayashi A; Tauchi H; Chayama K; Sekine T
J Toxicol Sci; 2009; 34 Suppl 2():SP251-7. PubMed ID: 19571477
[TBL] [Abstract][Full Text] [Related]
19. The effect of silibinin on experimental cyclosporine nephrotoxicity.
Zima T; Kameníková L; Janebová M; Buchar E; Crkovská J; Tesar V
Ren Fail; 1998 May; 20(3):471-9. PubMed ID: 9606735
[TBL] [Abstract][Full Text] [Related]
20. Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile.
Fields KK; Elfenbein GJ; Lazarus HM; Cooper BW; Perkins JB; Creger RJ; Ballester OF; Hiemenz JH; Janssen WE; Zorsky PE
J Clin Oncol; 1995 Feb; 13(2):323-32. PubMed ID: 7844593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
